Non-Small Cell Lung Cancer Market Regional Analysis

By region, the non-small cell lung cancer market is spread across North America, Europe, Asia-Pacific, and LAMEA. North America earned USD 5.6 billion in revenue from the non-small cell lung cancer therapies market in 2021, and it is projected that over the forecast period, it would hold a leading position of this market. The fact that between 80% and 85% of all occurrences of lung cancer are NSCLC is the main reason for the market's considerable and rapid expansion.

The acceptance of non-small cell lung cancer therapies is anticipated to increase with the rise in lung cancer risk factors, such as the percentage of smokers in the general population and exposure to toxins like asbestos and air pollution. Along with the other crucial medicines of chemotherapy and targeted therapy, the use of sophisticated immunotherapies is expanding in wealthy nations.